Panacea Biotec, India’s second largest producer of vaccines and a highly progressive research based health management company has bagged Government of India’s orders for supply of 345 million doses of Trivalent Oral Polio Vaccines (tOPV) and Bivalent Oral Polio Vaccine (bOPV) worth Rs 187.61 crore.
The order is to be supplied during the period December 2012 till May 2013 to meet the requirements of National Immunisation Days (NIDs) and Supplementary National Immunisation Days (SNIDs).
As per the order, the company will supply 125 million doses of tOPV in the month of December 2012 and 70 million doses of tOPV in the month of January 2013 for the NIDs. Besides, the company will also supply a total of 150 million doses of bOPV to meet the requirements of SNIDs - 100 million doses in the month of February 2013 and 50 million doses in the month of May 2013.
Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: